Breakdown | |||||
TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
8.64B | 36.35M | 29.36M | 40.11M | 39.45M | 22.77M | Gross Profit |
8.63B | 22.39M | 15.40M | 29.06M | 28.40M | 15.40M | EBIT |
-21.65M | -31.21M | -31.52M | -22.75M | -10.37M | -18.97M | EBITDA |
-17.17M | -29.18M | -30.00M | -22.01M | -9.71M | -18.74M | Net Income Common Stockholders |
-2.35B | -28.51M | -32.81M | -24.56M | -7.84M | -19.27M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
22.37M | 14.13M | 22.14M | 52.14M | 71.42M | 12.23M | Total Assets |
32.75M | 53.26M | 63.23M | 89.52M | 89.95M | 27.38M | Total Debt |
9.94M | 18.31M | 18.25M | 13.82M | 1.03M | 16.12M | Net Debt |
-12.43M | 4.18M | -3.89M | -38.32M | -70.39M | 3.89M | Total Liabilities |
15.81M | 29.99M | 27.86M | 26.94M | 10.73M | 23.96M | Stockholders Equity |
16.93M | 23.28M | 35.38M | 62.58M | 79.22M | 3.42M |
Cash Flow | Free Cash Flow | ||||
-19.17M | -22.59M | -34.69M | -18.29M | -7.29M | -18.28M | Operating Cash Flow |
-18.49M | -21.66M | -28.23M | -14.01M | -5.61M | -16.76M | Investing Cash Flow |
-681.16K | -936.24K | -6.46M | -4.28M | -1.68M | -1.52M | Financing Cash Flow |
21.37M | 14.47M | 4.96M | 715.20K | 66.35M | 8.18M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
72 Outperform | $14.17B | 24.40 | 3.87% | 1.83% | -0.57% | 8.25% | |
70 Outperform | $193.40B | 30.99 | 13.15% | 0.30% | 0.05% | 6.87% | |
64 Neutral | $81.57B | 19.89 | 97.86% | 1.88% | -18.72% | ― | |
62 Neutral | $11.73B | 13.27 | 159.08% | ― | 5.56% | 45.02% | |
61 Neutral | $58.67M | ― | -118.50% | ― | 1.80% | 33.06% | |
54 Neutral | $18.34B | 136.07 | -9.24% | 2.67% | -14.00% | -184.82% | |
49 Neutral | $6.84B | 0.05 | -53.14% | 2.48% | 24.49% | -3.26% |
CytoSorbents Corporation successfully closed an oversubscribed rights offering, raising $6.25 million in aggregate gross proceeds, which satisfies a debt covenant, unlocking $5 million in restricted cash. This financial maneuver significantly strengthens the company’s balance sheet, increasing liquidity by approximately $10.8 million, and supports their ongoing innovation and expansion efforts, particularly in pursuing U.S. and Canadian regulatory approval for DrugSorb-ATR.
CytoSorbents Corporation announced the commencement of a rights offering, distributing non-transferable Subscription Right Warrants to stockholders and certain warrantholders. The offering, which allows the purchase of units comprising common stock and warrants at $1.00 per unit, aims to raise capital and potentially strengthen the company’s market position, with implications for shareholder value and operational expansion.
CytoSorbents Corporation announced a rights offering, providing eligible stockholders and warrantholders the chance to purchase units consisting of common stock and warrants at a set price. This financial move could intrigue investors looking to expand their holdings, especially with the oversubscription privilege allowing for additional unit purchases. However, investors should act promptly as the rights and potential ownership stakes will expire without value if not exercised by January 10, 2025.